Thus, by enhancing the function of Type 17 T cells, 8–074 treatment increased the secretion of CCL20 in the tumor, promoting tumor infiltration of both CD8+ T and MoDC and making the anti-tumor immune response of Type 17 T cells efficient and persistent. This evidence concerns the gene CD8A and neoplasm.